The human microbiota consists of the trillions of symbiotic microbial cells harbored by each person, mainly bacteria in the gut, the human microbiome consists of the genes these cells harbor. The microbes including bacteria, fungi and viruses are the disease-causing microbes that accumulate over time and changing their gene activity & metabolic processes and resulting in an abnormal immune response against the substances and tissues that normally present in the human body. Microbiome projects across the globe have been launched with the aim to understand the roles that these symbionts play and their impacts on human health.
DuPont and Yakult Honsha Co., Ltd – Notable Market Players in Human Microbiome Market
Market leaders operating in the market have undertaken various organic growth strategies in the human microbiome market. The human microbiome market majorly consists of the players such as MaaT Pharma, ELIGO BIOSCIENCE, AOBiome, Kaleido Biosciences, Inc., Seres Therapeutics, Merck & Co., Inc, Yakult Honsha Co., Ltd, Rebiotix, Inc., DuPont de Nemours, Inc, and Synthetic Biologics, Inc. amongst others. Some of the activities undertaken by the company, which have promoted its growth are, product launch, approvals, partnership and strategy and business planning. Companies such MaaT Pharma, AOBiome, Seres Therapeutics, Inc and others have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market.
Below is the list of the growth strategies done by the players operating in the human microbiome market:
| Year | News |
| Jun-21 | MaaT Pharma received Data Safety and Monitoring Board (DSMB) approval to proceed to cohort study on phase 1b trial for testing capsule formulation of microbiome ecosystem therapy. |
| Jun-21 | Yakult Honsha Co., Ltd. has expanded its facility by construction of new plant in Mindanao, Philippines. The production capacity is planned to be 1.6 million bottles per day at the start of operations. The facilities will be expanded subsequently, and the Company expects the maximum production capacity to reach 3.2 million bottles per day. |
| Jun-21 | Seres Therapeutics, Inc. has received U.S. Food and Drug Administration (FDA) clearance for SER-155 under an Investigational New Drug (IND) application. SER-155 is an investigational oral, rationally-designed, cultivated microbiome therapeutic designed to reduce the incidence of gastrointestinal antibiotic-resistant bacterial infections, bacteremia and graft-versus-host disease (GvHD) in immunocompromised patients. |
| Jan-21 | Eligo Bioscience has entered research partnership with GlaxoSmithKline. This partnership is aimed at advancing Eligo biotics for the treatment or prevention of acne vulgaris with a pioneering CRISPR-based therapeutic for strain-specific microbiome modulation. |
| Jan-20 | Kaleido Biosciences, Inc. collaborated with Janssen’s World Without Disease Accelerator, part of the Janssen Pharmaceutical Companies of Johnson & Johnson. The collaboration is likely to explore the potential for Kaleido’s Microbiome Metabolic Therapies (MMT) for the prevention of the onset of childhood allergy and other atopic, immune, and metabolic conditions by driving specific microbiome features which support an appropriate maturation of the infant immune system. |
